Journal articleJ Am Soc Nephrol · March 12, 2026
KEY POINTS: Glucagon-like peptide-1 receptor agonists are increasingly used in patients with kidney failure despite trial exclusion. Initiation was associated with a 13% lower risk of cardiovascular events and 17% lower mortality versus dipeptidyl peptidas ...
Full textLink to itemCite
Journal articleClin J Am Soc Nephrol · January 21, 2026
KEY POINTS: The clinical frailty scale has the strongest psychometric validity in kidney disease apart from the physical frailty phenotype. Existing frailty instruments have strong predictive validity for mortality and hospitalizations across kidney diseas ...
Full textLink to itemCite
Journal articleAm J Kidney Dis · July 2025
RATIONALE & OBJECTIVE: Cardiac arrest is the leading cause of death for hemodialysis patients and often occurs within outpatient dialysis units. Approximately one-fifth of dialysis unit resuscitations are not initiated until emergency medical service perso ...
Full textLink to itemCite
ConferenceCirculation · November 12, 2024
Background:
Despite the substantial cardiovascular (CV) risk experienced by people with end-stage kidney disease (ESKD), few medications improve CV outcomes in this population. Glucagon-like peptide-1 ...
Full textCite
Journal articleJ Vis Exp · June 21, 2024
A range of conditions involving the kidneys and urinary bladder can cause organ-threatening complications that are preventable if diagnosed promptly with diagnostic imaging. Common imaging modalities include either computed tomography or diagnostic ultraso ...
Full textLink to itemCite
Journal articleRheumatology (Oxford) · May 30, 2022
OBJECTIVES: We evaluated the safety and efficacy of oral treprostinil in preventing progression of SSc-associated calcinosis. METHODS: This prospective open-label study enrolled 12 SSc patients meeting 2013 ACR/EULAR classification criteria with confirmed ...
Full textLink to itemCite
Journal articleClin Transl Oncol · October 2018
PURPOSE: Capecitabine has been studied as a radiosensitizer, and our study seeks to examine the association of concurrent capecitabine/radiation therapy (RT) on event-free- (EFS) and overall survival (OS) in women with breast cancer (BC) with residual dise ...
Full textLink to itemCite
Journal articleBreast Cancer Res Treat · January 2018
BACKGROUND: Obesity may negatively affect survival in breast cancer (BC), but studies are conflicting, and associations may vary by tumor subtypes and race/ethnicity groups. METHODS: In a retrospective review, we identified 273 women with invasive BC admin ...
Full textLink to itemCite
Journal articleJournal of Clinical Oncology · May 20, 2017
e12136 Background: Obesity may adversely influence survival in breast cancer; however, studies are conflicting and limited in the neoadjuvant setting. Results may also vary by tumor subtype and race/ethnicity. Our study seeks to ...
Full textCite
Journal articleJournal of Clinical Oncology · May 20, 2017
e12117 Background: Capecitabine has been studied as a radiosensitizer in rectal cancer, but its role in BC is unclear. Our study seeks to examine the association of concurrent capecitabine/radiation therapy (RT) on survival in wo ...
Full textCite